Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 17/20 | 1.00 |
| ▸ | TACR1 | P25103 | 16/20 | 1.00 |
| ▸ | TACR3 | P29371 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | CCR5 | P51681 | 2/20 | 0.65 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Osanetant SCHEMBL119440 | 1.00 | TACR2 (1.00) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Osanetant SCHEMBL30961738 | 1.00 | TACR2 (1.00) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Osanetant SCHEMBL5679271 | 1.00 | TACR2 (1.00) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Osanetant SCHEMBL29371450 | 1.00 | TACR2 (1.00) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Osanetant SCHEMBL5679471 | 0.99 | TACR2 (0.98) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Osanetant SCHEMBL6543149 | 0.99 | TACR2 (0.98) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL8136920 | 0.97 | TACR2 (0.95) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL6543864 | 0.97 | TACR2 (0.94) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL24855515 | 0.96 | TACR2 (0.92) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL31224281 | 0.96 | TACR2 (0.92) | TACR2TACR1TACR3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3169700-A1 | ANTAGONISTS OF NEUROKININ B IN FISH REPRODUCTION | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. (IL) | 2017-05-24 | — | — | EP | claimed |
| WO-2016009439-A1 | ANTAGONISTS OF NEUROKININ B IN FISH REPRODUCTION | YISSUME RESEARCH DEVELOMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-01-21 | — | — | WO | claimed |
| EP-0858325-B1 | STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION | SANOFI SYNTHELABO (FR) | 2002-07-31 | — | — | EP | claimed |
| US-6284277-B1 | NONPROTEIN | SANOFI-SYNTHELABO (FR) | 2001-09-04 | — | — | US | claimed |
| US-20220167645-A1 | METHODS OF IMPROVING FISH FEED CONVERSION RATE AND SURVIVAL | AQUINOVO LTD. (IL) | 2022-06-02 | — | — | US | disclosed |
| EP-3937965-A1 | METHODS OF IMPROVING FISH FEED CONVERSION RATE AND SURVIVAL | Aquinovo Ltd. (IL) | 2022-01-19 | — | — | EP | disclosed |
| US-10793614-B2 | Antagonists of fish reproduction | Yissum Research Development Company of the Hebrew University ofJerusaIem Ltd. (IL) | 2020-10-06 | — | — | US | disclosed |
| WO-2020183463-A1 | METHODS OF IMPROVING FISH FEED CONVERSION RATE AND SURVIVAL | AQUINOVO LTD. (IL) | 2020-09-17 | — | — | WO | disclosed |
| US-20190169256-A1 | ANTAGONISTS OF FISH REPRODUCTION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2019-06-06 | — | — | US | disclosed |
| US-10201568-B2 | Brain, spinal, and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2019-02-12 | — | — | US | disclosed |
| US-10155790-B2 | Antagonists of neurokinin B in fish reproduction | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-12-18 | — | — | US | disclosed |
| US-20180071333-A1 | BRAIN, SPINAL, AND NERVE INJURY TREATMENT | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2018-03-15 | — | — | US | disclosed |
| EP-0858325-B1 | STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION | SANOFI SYNTHELABO (FR) | 2002-07-31 | — | — | EP | disclosed |
| US-6342607-B1 | INTERMEDIATES FOR PREPARATION OF NEUROKININ ANTAGONISTS | SANOFI-SYNTHELABO (FR) | 2002-01-29 | — | — | US | disclosed |
| EP-0888304-B1 | SUBSTITUTED 3-ARYL-3-CARBOXYALKYL GLUTARAMIDES, METHOD FOR PREPARING SAME BY 4-ARYLO-4-CYANOHEPTANE DICARBOXYLIC ACID CYCLISATION, AND USE THEREOF FOR PREPARING 3-ARYL-3-HYDROXYALKYLPIPERIDINES | SANOFI SYNTHELABO (FR) | 2001-10-04 | — | — | EP | disclosed |
| US-6284277-B1 | NONPROTEIN | SANOFI-SYNTHELABO (FR) | 2001-09-04 | — | — | US | disclosed |
| US-6242607-B1 | SUCH AS 4-CYANO-4-(3,4-DICHLOROPHENYL)HEPTANEDIOIC ACID USED AS ANTAGONISTS OF NEUROKININES | SANOFI-SYNTHELABO (FR) | 2001-06-05 | — | — | US | disclosed |
| US-6008360-A | Substituted 3-aryl-3-carboxyalkyl glutaramides, method for preparing same by 4-arylo-4-cyanoheptane dicarboxylic acid cyclisation, and use thereof for preparing 3-aryl-3-hydroxyalkylpiperidines | SANOFI-SYNTHELABO (FR) | 1999-12-28 | — | — | US | disclosed |
| EP-0858325-A1 | STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION | SANOFI (FR) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997017064-A1 | STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION | SANOFI (FR) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071333-A1 | BRAIN, SPINAL, AND NERVE INJURY TREATMENT | TACR1, TACR2, NPSR1 | TACR2 2/4885TACR1 1/4885TACR3 43/4885 |
| US-10201568-B2 | Brain, spinal, and nerve injury treatment | TACR1, TACR2, NPSR1 | TACR2 2/4885TACR1 1/4885TACR3 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.